A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005. A single institution experience

Lung Cancer

Volumn 55, Issue 3, 2007, Pages 379-387

  Metintas, Muzaffer ^a   Ak, Guntulu ^a   Erginel, Sinan ^a   Alatas, Fusun ^a   Yildirim, Huseyin ^a   Kurt, Emel ^a   Metintas, Selma ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Best supportive care; Chemotherapy; Mesothelioma; Prognosis; Therapy

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIFFUSE MALIGNANT PLEURAL MESOTHELIOMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 33847287409     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.11.005     Document Type: Article

References (35)

1. Antman K.H., Shemin R., Ryan L., et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades 1965-1985. J Clin Oncol 6 (1988) 147-153
2. Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 16 (1998) 145-152
3. De Klerk N.H., and Musk A.W. Epidemiology of mesothelioma. In: Robinson B.W.S., and Chahinian A.P. (Eds). Mesothelioma (2002), Martin Dunitz Ltd., London 339-350
4. Herndon J.E., Green M.R., Chahinian P., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
5. Sugarbaker D.J., Jaklitsch M.T., and Liptay M.J. Mesothelioma and radical multimodality therapy: who benefits?. Chest 107 Suppl (1995) 345S-350S
6. Sugarbaker D.J., and Norberto J.J. Multimodality management of malignant pleural mesothelioma. Chest 113 Suppl (1998) 61S-65S
7. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 56 (2001) 250-265
8. Tomek S., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 45 Suppl (2004) 103S-119S
9. Metintas M., Özdemir N., Uçgun I., et al. Cisplatin, mitomycin, and interferon-α2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 116 (1999) 391-398
10. Hunt K.J., Longton G., Williams M.A., et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 109 (1996) 1239-1242
11. Ryan J.W., Herndon J., and Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest 113 Suppl (1998) 66S-73S
12. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
13. Ong S.T., and Vogelzang N.J. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14 (1996) 1007-1017
14. Sterman D.H., Kaiser L.R., and Albelda S.M. Advances in the treatment of malignant pleural mesothelioma. Chest 116 (1999) 504-520
15. Shin D.M., Fossella F.B., Putnam J.B., et al. Phase II study of combination chemotherapy with cytoxan, adriamycine, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Proc Am Soc Clin Oncol 12 (1993) 398
16. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 (1999) 25-30
17. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
18. ©) and Oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 (2003) 349-354
19. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
20. Chahinian A.P., Antman K., Goutsou M., et al. Randomized phase II trial of cisplatin with mitomycine or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group. Br J Clin Oncol 11 (1993) 1559-1565
21. Vogelzang N.J., Weissman L.B., Herndon J.E., et al. Trimetrexate in malignant mesothelioma: a cancer and leukemia group B phase II study. J Clin Oncol 12 (1994) 1436-1442
22. van Ruth S., Baas P., and Zoetmulder F.A. Surgical treatment of malignant pleural mesothelioma: a review. Chest 123 (2003) 551-561
23. Peto J., Decarli A., Vecchia C., et al. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
24. Rusch V.S., and Ginsberg R.J. New concepts in the staging of mesotheliomas. In: Deslauriers J., and Lacquet L.K. (Eds). International trends in general thoracic surgery (1990), CV Mosby, St. Louis 336-343
25. Hermanek P., and Sobin L.H. TNM classification of malignant tumours. 4th ed., 2nd revision (1992), UICC International Union Against Cancer
26. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108 (1995) 1122-1128
27. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
28. Novak A.K., Byrne M.J., Williamson R., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 (2002) 491-496
29. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Neth Cancer Inst 92 (2000) 205-216
30. Britton M. The epidemiology of mesothelioma. Semin Oncol 29 (2002) 18-25
31. Boutin C., Schlesser M., Frenay C., and Astoul Ph. Malignant pleural mesothelioma. Eur Respir J 12 (1998) 972-981
32. Tomek S., Emri S., Krejcy K., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 88 (2003) 167-174
33. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 (2005) 429-434
34. Sugarbaker D.J., Garcia J.P., Richards W.G., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 (1996) 288-294
35. Rusch V.W., and Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68 (1999) 1799-1804